Gilead Sciences Inc (GILD)vsViking Holdings Ltd (VIK)
GILD
Gilead Sciences Inc
$131.33
-2.04%
HEALTHCARE · Cap: $166.40B
VIK
Viking Holdings Ltd
$82.67
-1.55%
CONSUMER CYCLICAL · Cap: $37.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 353% more annual revenue ($29.44B vs $6.50B). GILD leads profitability with a 28.9% profit margin vs 17.6%. GILD trades at a lower P/E of 18.2x. GILD earns a higher WallStSmart Score of 72/100 (B).
GILD
Strong Buy72
out of 100
Grade: B
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+43.2%
Fair Value
$236.08
Current Price
$131.33
$104.75 discount
Intrinsic value data unavailable for VIK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Every $100 of equity generates 255 in profit
Earnings expanding 226.6% YoY
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
4.7% revenue growth
Premium valuation, high expectations priced in
Trading at 33.7x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : VIK
The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
GILD profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK carries more volatility with a beta of 1.57 — expect wider price swings.
VIK is growing revenue faster at 27.8% — sustainability is the question.
GILD generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
GILD scores higher overall (72/100 vs 66/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?